Altimmune's (ALT) Buy Rating Reaffirmed at HC Wainwright

Altimmune (NASDAQ:ALT - Get Free Report)'s stock had its "buy" rating reissued by equities researchers at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They currently have a $12.00 target price on the stock. HC Wainwright's target price would indicate a potential upside of 226.98% from the stock's current price.

Several other equities research analysts have also commented on the company. Stifel Nicolaus began coverage on Altimmune in a research report on Wednesday, January 8th. They issued a "buy" rating and a $18.00 price objective on the stock. William Blair reiterated a "market perform" rating on shares of Altimmune in a research report on Friday, March 14th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Altimmune currently has a consensus rating of "Moderate Buy" and an average price target of $20.83.

Altimmune Stock Down 7.8 %

Shares of Altimmune stock traded down $0.31 during midday trading on Thursday, hitting $3.67. The company had a trading volume of 2,750,528 shares, compared to its average volume of 2,923,375. The company has a fifty day simple moving average of $5.95 and a 200 day simple moving average of $6.93. The stock has a market cap of $282.64 million, a price-to-earnings ratio of -2.37 and a beta of 0.91. Altimmune has a 12-month low of $3.56 and a 12-month high of $11.16.

Altimmune (NASDAQ:ALT - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) EPS for the quarter, topping analysts' consensus estimates of ($0.34) by $0.01. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The company had revenue of $0.01 million during the quarter, compared to analysts' expectations of $0.00 million. As a group, analysts expect that Altimmune will post -1.35 EPS for the current year.

Insiders Place Their Bets

In other Altimmune news, CFO Gregory L. Weaver bought 10,000 shares of the firm's stock in a transaction on Thursday, March 13th. The shares were acquired at an average cost of $5.20 per share, with a total value of $52,000.00. Following the purchase, the chief financial officer now directly owns 10,000 shares of the company's stock, valued at $52,000. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 4.10% of the stock is owned by company insiders.

Institutional Trading of Altimmune

Several large investors have recently added to or reduced their stakes in the stock. Intech Investment Management LLC purchased a new position in shares of Altimmune during the 3rd quarter worth $207,000. Charles Schwab Investment Management Inc. raised its stake in Altimmune by 2.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company's stock worth $1,299,000 after purchasing an additional 4,772 shares during the period. FMR LLC boosted its holdings in Altimmune by 546.8% in the 3rd quarter. FMR LLC now owns 51,060 shares of the company's stock valued at $314,000 after purchasing an additional 43,166 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of Altimmune by 318.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 42,140 shares of the company's stock valued at $259,000 after buying an additional 32,072 shares during the period. Finally, Centiva Capital LP acquired a new stake in shares of Altimmune during the 3rd quarter worth approximately $120,000. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.